Navigation Links
Kuros Announces Allowance of US Patent for the Local Application of Parathyroid Hormone (PTH) for Bone Healing
Date:7/18/2011

ZURICH, July 19, 2011 /PRNewswire/ --


 

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has received Notice of Allowance for U.S. 11/679,807 from the U.S. Patent Office. The now allowed application acknowledges that Kuros has been first in showing that parathyroid hormone (PTH) when applied locally in a matrix to a bone defect has the ability to improve bone healing. Kuros has already demonstrated the clinical utility of this proprietary approach to bone healing in two large phase II studies in trauma patients which have reported previously.

Kuros is developing a portfolio of biomaterial, and bioactive-biomaterial combination, products. The Company's product candidates are based on two different matrix technology platforms.  Kuros' most advanced products are based on a fibrin matrix and include KUR-111 and KUR-113 which have achieved positive results in large Phase II trials for tibial plateau fractures and tibial shaft fractures respectively.

 Didier Cowling, Chief Executive Officer at Kuros says: "This patent will give Kuros broad protection on the concept of locally applied PTH to improve bone healing. Obtaining the notice of allowance for this US patent application further builds on Kuros' proprietary position in local treatments for bone generation and healing".

The Notice of Allowance for US 11/679,807 with its broad scope of protection follows US 7,247,609, US 6,331,422, US 6,607,740, EP 1 465 989, EP 1 124 590, EP 1 280 566 and patents in many other countries which protect Kuros` approach with PTH and its incorporation into matrices for local therapeutic applications.

About Kuros

http://www.kuros.ch

Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications.

Kuros has two biomaterial technology platforms, one based on fibrin sealants and the other based on its own proprietary synthetic technology that can mimic fibrin in many of its attributes.  These materials can be used alone or in combination with biologically active molecules.

Kuros' combination products are designed to mimic the body's natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecules into the injectable matrices aims to maximize their activity by retention at the site of action. Kuros products are designed to combine ease of application with localized delivery.  Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules.

Kuros' has a diverse pipeline of product candidates with its most advanced product candidates being in trauma and wound care.

Since its creation, Kuros has raised over $150 million. The company is located in Zurich, Switzerland.

Press Enquiries

Kuros
Didier Cowling, CEO +41(0)44-200-56-62
Alistair Irvine, Director of Business Development +41(0)44-200-56-62

For Swiss Media Enquires:
IRF Communications
Martin Meier-Pfister +41(0)43-244-81-40
Jan Gregor +41(0)43-244-81-54

For International Media Enquires:
Citigate Dewe Rogerson
David Dible, Nina Enegren +44(0)207-638-9571



'/>"/>
SOURCE Kuros Biosurgery AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... N.C. , Feb. 11, 2016 ... leading provider of custom manufacturing and development services ... expanded sterile fill-finish capabilities and capacity in its ... growth in demand has driven several recent investments. ... 2001 it had one filling line with small-scale ...
(Date:2/11/2016)... de fevereiro de 2016  A Proliant Biologicals ... de soroalbumina bovina (BSA -- Bovine Serum ... na Ilha Norte da Nova Zelândia, em Feilding. ... na fábrica da Proliant nos EUA, localizada em ... e instalação dos equipamentos foram feitos de forma ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets ... (APAC) breast cancer market will experience considerable expansion ... at a Compound Annual Growth Rate (CAGR) of 8.5%. ... - states that the Asia-Pacific ... billion in 2014 to $3.4 billion by 2021, at a ...
Breaking Medicine Technology:
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Registered nurses, ... free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on Thursday, ... in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, who ...
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of Pain ... 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier B.V.) ... number of citations received by the journal over a three year period and also ...
(Date:2/11/2016)... IL (PRWEB) , ... February 11, 2016 , ... ... to the healthcare industry, ranked among the top five firms in the “2015/2016 ... and HIT Implementation Support and Staffing. KLAS is a research and insights firm ...
(Date:2/11/2016)... ... 11, 2016 , ... Thermi™, a world leader in thermistor-regulated ... the promotions of Allison Kelly to executive vice president of the company’s new ... of North American capital sales, and Wendy Oseas to vice president of global ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... an unparalleled clinical decision support technology, with highly adaptable algorithms, has been updated ... a patient has signs and symptoms consistent with Zikas and a travel history ...
Breaking Medicine News(10 mins):